Source: Asian Venture Capital Journal

XWPharma: Panacea leads $40m Series C for China's XWPharma

Healthcare-focused Panacea Venture has led a $40 million Series C round for China's XWPharma, a neurobiology-focused biotech developer previously known as XW Laboratories.

Read full article »
XWPharma's Competitors | XWPharma's News | XWPharma's Financials
Stay up-to-date with the latest news on XWPharma
Est. Annual Revenue
$100K-5.0M
Est. Employees
1-25
Leonard Blum's photo - President & CEO of XWPharma

President & CEO

Leonard Blum

CEO Approval Rating

90/100

Read more
Stay up-to-date with the latest news on XWPharma